Home » Posts tagged 'westhouse securities'

Tag Archives: westhouse securities

Advanced Oncotherapy – Change of name of NOMAD & Joint Broker

AVO1Change of name of Nominated Adviser and Joint Broker


The Company notifies that its Nominated Adviser and Joint Broker has changed its registered name from Westhouse Securities Limited to Stockdale Securities Limited.

Advanced Oncotherapy Plc


Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy’s team “ADAM” based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc to operate the Company’s proton beam cancer therapy centre in Harley Street.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Advanced Oncotherapy – Broker Notes

AVO1Advanced Oncotherapy

Broker Notes

Westhouse retains a Buy recommendation with a Target Price of 25p.

Advanced Oncotherapy (AVO) – Analyst Robert Sanders – On Schedule. Two CCL modules are announced as ready for high-power testing. This is the first time two CCL modules will be tested together…the finished proton beam cancer treatment machine (LIGHT system) will incorporate 10 CCL units/15 CCL modules in a series so that protons are accelerated to the necessary speed to treat radiosensitive tumours. AVO has to date been hitting all of its previously set-out milestones. Westhouse Securities said in a note growing awareness of proton therapy as a treatment for cancer should ensure strong demand for Advanced Oncotherapy’s LIGHT system. Analyst Robert Sanders said Monday’s news showed the company was on track to have its treatment on track for 2017.

Beaufort Securities has a Speculative Buy rating.

Says the High-power testing of LIGHT’s individual components and modules at this stage is a crucial demonstration of their ability to perform to specifications. Initial low power testing has shown that they perform to expectations and it is realistic to expect that the successful conclusion of these tests to build confidence that the CCL modules can work under the required conditions to deliver the high energy protons required to treat patients effectively. Results from this work should be expected during Q4’15, before moving onto to running the modules in series as a bank of accelerators. Once demonstrated, the most significant technological hurdle will have been successfully negotiated, leaving only a number of less challenging barriers ahead. While Beaufort considers that the FDA could potentially hinder product approval for rather longer than might presently be anticipated, the extent of interest from other non-dependent territories (in particular that presently being shown from China) suggests the Group is likely to be overwhelmed by demand for LIGHT as soon as commercial units become available. The enormity of this opportunity and the market potential it presents has already been significantly detailed in Beaufort initiation research of September 2014 and subsequent updates. In simple terms, if AVO delivers exactly ‘what it says on the tin’, the operational and cost advantages LIGHT offers will effectively render first generation proton therapy devices all but obsolete. Its principal limitation would then become simply its capacity to deliver to a global opportunity that will grow dramatically beyond its current US$2.5bn size, as it will also become the natural replacement for the more antiquated X-ray radiation machines that are installed in huge numbers around the globe. Given such an outcome, of course, major international competitors wishing to remain in the game will almost certainly be willing to pay a handsome price, one way or another, to get their hands on AVO’s proprietary technologies. Advanced Oncotherapy plc remains one of Beaufort’s key investment picks for 2015. Beaufort Securities acts as corporate broker to Advanced Oncotherapy plc

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.